Ciraparantag

Ciraparantag

• CAS Number: 1438492-26-2
• UNSPSC Description: Ciraparantag is a thrombin and factor Xa inhibitor. Ciraparantag is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban[1][2][3][4].
• Target Antigen: Factor Xa
• Type: Reference compound
• Related Pathways: Metabolic Enzyme/Protease
• Applications: COVID-19-immunoregulation
• Field of Research: Cardiovascular Disease
• Assay Protocol: https://www.medchemexpress.com/ciraparantag.html
• Purity: 98.0
• Solubility: H2O : ≥ 31 mg/mL
• Smiles: O=C(NCCCN1CCN(CCCNC([C@@H](N)CCCNC(N)=N)=O)CC1)[C@@H](N)CCCNC(N)=N
• Molecular Weight: 512.70
• References & Citations: [1]Das A, et al. Novel antidotes for target specific oral anticoagulants. Exp Hematol Oncol. 2015 Sep 15;4:25.|[2]Gomez-Outes A, et al. Specific antidotes in development for reversal of novel anticoagulants: a review. Recent Pat Cardiovasc Drug Discov. 2014;9(1):2-10.|[3]Hu TY, et al. Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vasc Health Risk Manag. 2016 Feb 17;12:35-44.|[4]Honickel M, et al. The Reversal of Direct Oral Anticoagulants in Animal Models. Shock. 2017 Aug;48(2):144-158.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, stored under nitrogen)
• Clinical Information: Phase 2